Lifecore Biomedical, Inc. (LFCR) stock

LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25

Financials through Q3 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30

$6.42+0.02 (+0.31%)

Close on Nov 13, 2026Market cap $243.02MP/E –Yield –

Lifecore Biomedical EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Lifecore Biomedical's EV/EBITDA was 51.0× on Dec 30, 2022, against 43.2× a year earlier. Over the last 5 years it ranged from 12.2× to 132.9×, with a median of 21.2×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2022	Dec 30, 2022	51.0×	+7.8
2021	Dec 31, 2021	43.2×	+14.9
2020	Mar 31, 2020	28.3×	+4.8
2019	Dec 31, 2019	23.5×	+7.7
2018	Dec 31, 2018	15.9×	−0.9
2017	Dec 29, 2017	16.8×	+4.1
2016	Mar 31, 2016	12.7×	−0.6
2015	Dec 31, 2015	13.3×	−0.8
2014	Dec 31, 2014	14.2×	+2.9
2013	Dec 31, 2013	11.3×	−2.2
2012	Dec 31, 2012	13.5×	+3.2
2011	Dec 30, 2011	10.3×	–

Where these numbers come from

Parsed from the XBRL in Lifecore Biomedical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing